Key Insights

Highlights

Treatment Research

2 treatments under study, led by Bevacizumab Modified Folfirinox

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT05512208Phase 2Recruiting

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

NCT05665023Phase 2UnknownPrimary

Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma

Showing all 2 trials

Research Network

Common Treatments

  • Bevacizumab Modified Folfirinox1
  • Avutometinib Vs6766 Defactinib1

Active Sponsors

  • Verastem, Inc.1
  • University of Oklahoma1
  • Yonsei University1

Top Investigators

Related Conditions

  • High Grade Serous Ovarian Cancer1
  • Solid Tumor1
  • Primary Peritoneal Cancer1
  • Cervical Cancer1
  • Endometrioid Cancer1

Activity Timeline